Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ, Rini BI, McDermott DF, Arén Frontera O, Hammers HJ, Carducci MA, Salman P, Escudier B, Beuselinck B, Amin A, Porta C, George S, Neiman V, Bracarda S, Tykodi SS, Barthélémy P, Leibowitz-Amit R, Plimack ER, Oosting SF, Redman B, Melichar B, Powles T, Nathan P, Oudard S, Pook D, Choueiri TK, Donskov F, Grimm MO, Gurney H, Heng DYC, Kollmannsberger CK, Harrison MR, Tomita Y, Duran I, Grünwald V, McHenry MB, Mekan S, Tannir NM; CheckMate 214 investigators.

Lancet Oncol. 2019 Aug 16. pii: S1470-2045(19)30413-9. doi: 10.1016/S1470-2045(19)30413-9. [Epub ahead of print]

PMID:
31427204
2.

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.

Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP.

Prostate. 2019 Aug;79(11):1326-1337. doi: 10.1002/pros.23839. Epub 2019 Jun 18.

PMID:
31212368
3.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.

PMID:
31157964
4.

Prognostic Utility of a Whole-blood Androgen Receptor-based Gene Signature in Metastatic Castration-resistant Prostate Cancer.

Kwan EM, Fettke H, Docanto MM, To SQ, Bukczynska P, Mant A, Pook D, Ng N, Graham LK, Mangiola S, Segelov E, Mahon K, Davis ID, Parente P, Pezaro C, Todenhöfer T, Horvath LG, Azad AA.

Eur Urol Focus. 2019 May 15. pii: S2405-4569(19)30139-7. doi: 10.1016/j.euf.2019.04.020. [Epub ahead of print]

PMID:
31103601
5.

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.

Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, Priou F, Langkilde NC, Novikov A, Kantoff PW.

J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.

PMID:
30817251
6.

Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.

Ha FJ, Spain L, Dowling A, Kwan EM, Pezaro C, Day D, Chia PL, Tran B, Pook D, Weickhardt AJ.

Asia Pac J Clin Oncol. 2019 Jan 30. doi: 10.1111/ajco.13109. [Epub ahead of print]

PMID:
30701671
7.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.

PMID:
30049486
8.

Prevalence of systemic anticancer therapy for patients within the last 30 days of life: experience in a private hospital oncology group.

Wein L, Rowe C, Brady B, Handolias D, Lipton L, Pook D, Stanley R, Haines I.

Intern Med J. 2017 Mar;47(3):280-283. doi: 10.1111/imj.13260.

PMID:
27658500
9.

Establishment of primary patient-derived xenografts of palliative TURP specimens to study castrate-resistant prostate cancer.

Lawrence MG, Pook DW, Wang H, Porter LH, Frydenberg M, Kourambas J, Appu S, Poole C, Beardsley EK, Ryan A, Norden S, Papargiris MM, Risbridger GP, Taylor RA.

Prostate. 2015 Sep;75(13):1475-83. doi: 10.1002/pros.23039. Epub 2015 Jul 14.

PMID:
26177841
10.

Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.

Risbridger GP, Taylor RA, Clouston D, Sliwinski A, Thorne H, Hunter S, Li J, Mitchell G, Murphy D, Frydenberg M, Pook D, Pedersen J, Toivanen R, Wang H, Papargiris M, Lawrence MG, Bolton DM.

Eur Urol. 2015 Mar;67(3):496-503. doi: 10.1016/j.eururo.2014.08.007. Epub 2014 Aug 22.

PMID:
25154392
11.

A pro-tumourigenic loop at the human prostate tumour interface orchestrated by oestrogen, CXCL12 and mast cell recruitment.

Ellem SJ, Taylor RA, Furic L, Larsson O, Frydenberg M, Pook D, Pedersen J, Cawsey B, Trotta A, Need E, Buchanan G, Risbridger GP.

J Pathol. 2014 Sep;234(1):86-98. doi: 10.1002/path.4386. Epub 2014 Jul 9.

PMID:
25042571
12.

Rare synchronous metastases of renal cell carcinoma.

Rajarubendra N, Pook D, Frydenberg M, Appu S.

Urol Ann. 2014 Apr;6(2):157-8. doi: 10.4103/0974-7796.130652.

13.

Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.

McGrath MJ, Binge LC, Sriratana A, Wang H, Robinson PA, Pook D, Fedele CG, Brown S, Dyson JM, Cottle DL, Cowling BS, Niranjan B, Risbridger GP, Mitchell CA.

Cancer Res. 2013 Aug 15;73(16):5066-79. doi: 10.1158/0008-5472.CAN-12-4520. Epub 2013 Jun 25.

14.

A preclinical xenograft model identifies castration-tolerant cancer-repopulating cells in localized prostate tumors.

Toivanen R, Frydenberg M, Murphy D, Pedersen J, Ryan A, Pook D, Berman DM; Australian Prostate Cancer BioResource, Taylor RA, Risbridger GP.

Sci Transl Med. 2013 May 29;5(187):187ra71. doi: 10.1126/scitranslmed.3005688.

15.

A bioengineered microenvironment to quantitatively measure the tumorigenic properties of cancer-associated fibroblasts in human prostate cancer.

Clark AK, Taubenberger AV, Taylor RA, Niranjan B, Chea ZY, Zotenko E, Sieh S, Pedersen JS, Norden S, Frydenberg M, Grummet JP, Pook DW; Australian Prostate Cancer BioResource, Stirzaker C, Clark SJ, Lawrence MG, Ellem SJ, Hutmacher DW, Risbridger GP.

Biomaterials. 2013 Jul;34(20):4777-85. doi: 10.1016/j.biomaterials.2013.03.005. Epub 2013 Apr 2.

PMID:
23562048
16.

A preclinical xenograft model of prostate cancer using human tumors.

Lawrence MG, Taylor RA, Toivanen R, Pedersen J, Norden S, Pook DW, Frydenberg M; Australian Prostate Cancer BioResource, Papargiris MM, Niranjan B, Richards MG, Wang H, Collins AT, Maitland NJ, Risbridger GP.

Nat Protoc. 2013 May;8(5):836-48. doi: 10.1038/nprot.2013.043. Epub 2013 Apr 4.

PMID:
23558784
17.

Breaking through a roadblock in prostate cancer research: an update on human model systems.

Toivanen R, Taylor RA, Pook DW, Ellem SJ, Risbridger GP.

J Steroid Biochem Mol Biol. 2012 Sep;131(3-5):122-31. doi: 10.1016/j.jsbmb.2012.01.005. Epub 2012 Feb 8. Review.

PMID:
22342674
18.

Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma.

Azad A, Herbertson RA, Pook D, White S, Mitchell PL, Tebbutt NC.

Acta Oncol. 2009;48(4):619-21. doi: 10.1080/02841860802495362. No abstract available.

PMID:
18979266
19.

Detection of hypoxia in human squamous cell carcinoma by EF5 binding.

Evans SM, Hahn S, Pook DR, Jenkins WT, Chalian AA, Zhang P, Stevens C, Weber R, Weinstein G, Benjamin I, Mirza N, Morgan M, Rubin S, McKenna WG, Lord EM, Koch CJ.

Cancer Res. 2000 Apr 1;60(7):2018-24.

20.

[Clotrimazole in a new formula].

Pook D.

Med Welt. 1982 Apr 2;33(13):487-9. German. No abstract available.

PMID:
7087725
21.

[The efficacy of clotrimazole].

Pook D.

Med Welt. 1980 May 23;31(21):823-4. German. No abstract available.

PMID:
7392939

Supplemental Content

Support Center